FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma

被引:0
作者
Toru Nagasaka
Masaharu Gunji
Noboru Hosokai
Kumiko Hayashi
Hiroshi Ikeda
Masafumi Ito
Suguru Inao
机构
[1] Japanese Red Cross Nagoya First Hospital,Department of Neurosurgery
[2] Japanese Red Cross Nagoya First Hospital,Department of Pathology
[3] Mitsubishi Kagaku Bio-Clinical Laboratories,undefined
[4] Inc.,undefined
来源
Brain Tumor Pathology | 2007年 / 24卷
关键词
Glioblastoma; Oligodendroglioma; Fluorescence in situ hybridization; 1p/19q imbalance; CDKN2A deletion;
D O I
暂无
中图分类号
学科分类号
摘要
Glioblastoma is the most malignant and frequent of the glial tumors. A minor fraction of glioblastoma may contain areas showing oligodendroglioma-like tumor cell differentiation. Several authors have described such tumors as glioblastoma with oligodendroglial component (GBMO). GBMO may represent the ultimate level of malignancy in the oligodendroglial lineage. The oligodendroglial component and combined loss of chromosomal arm 1p and 19q in glioblastoma indicate increased survival. In our study, we analyzed 1p and 19q status in a series of 12 glioblastoma and 8 oligodendroglial tumors using fluorescence in situ hybridization (FISH) on paraffin-embedded tissues. In each case, hybridization status was classified as deletion, imbalance, polysomy, amplification, or normal pattern. Other genetic alterations such as CDKN2A (p16), RB, and EGFR were also assessed. On histological review, 2 of 12 glioblastoma (16.7%) were classified as GBMO. Chromosome 1p/19q deletion was detected in 3 of 12 glioblastomas (25%). In contrast, all 8 oligodendroglial tumors showed 1p/19q deletion. All GBMO had 19q deletion with imbalance, whereas 1 of 10 ordinary glioblastoma (10%) demonstrated 19q deletion with imbalance. All but 1 ordinary glioblastoma (90%) showed CDKN2A (p16) deletion, but no GBMO displayed this alteration. Our results indicate that GBMO may be a distinct subtype of glioblastoma harboring a characteristic molecular profile. FISH on paraffin-embedded specimens is a useful method for subclassification of glioblastoma.
引用
收藏
页码:1 / 5
页数:4
相关论文
共 38 条
  • [1] Kraus JA(2001)Molecular genetic alterations in glioblastomas with oligodendroglial component Acta Neuropathol (Berl) 101 311-320
  • [2] Lamszus K(1997)Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02 Int J Radiat Oncol Biol Phys 38 911-914
  • [3] Glesmann N(1996)Glioblastoma with oligodendroglial features (GBM-OL): report from Radiation Therapy Oncology Group (RTOG) trial 8302 Lab Invest 74 141A-871
  • [4] Donahue B(2001)Glioblastomas with an oligodendroglial component: a pathological and molecular study J Neuropathol Exp Neurol 60 863-328
  • [5] Scott CB(2002)Impact of genotype and morphology on the prognosis of glioblastoma J Neuropathol Exp Neurol 61 321-802
  • [6] Nelson JS(1998)Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-associated microscopy J Neuropathol Exp Neurol 57 791-386
  • [7] Nelson JS(1999)Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization Am J Pathol 155 375-50
  • [8] Petito CK(2001)SIOP Europe Neuroblastoma Pathology, Biology, and Bone Marrow Group: pathology and biopsy guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines Med Pediatr Oncol 37 40-655
  • [9] Scott CB(2005)Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643-6845
  • [10] He J(2005)Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study J Clin Oncol 23 6838-9